drugset / Trial / NCT05429775
In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects
Non-randomizedCrossoverOpen-labelOther
Summary
This is a single centre, open-label, sequential, single dose 4-period crossover, scintigraphic imaging study in healthy male and non-pregnant, non-lactating female subjects.
Timeline
- Start
- 2018-12-26
- Primary completion
- 2019-01-29
- Completion
- 2019-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 2 mg | Oral |
Indications
No indication recorded.